STAR PipelineDog

STAR-K9E2

Canine obesity and metabolic disease · GLP-1 / GIP dual agonist

Overview

Species: Dog
Indication: Canine obesity and metabolic disease
Target: GLP-1 / GIP
Modality: GLP-1 / GIP dual agonist
Current Stage: Cell Line
Route: Out-licensing at POC

Out-Licensing

Why It Matters

The Next-Generation Dual Agonist

GLP-1 / GIP dual agonists have been clinically validated in human obesity. We build the dual agonist on the caninization experience from STAR-K9E.

Dual target — GLP-1 and GIP

K9E

Inherits K9E caninization

Mechanism of action

GLP-1 receptor agonist acting on the brain, stomach and pancreas — Fig. 1. A once-weekly GLP-1 receptor agonist acts at GLP-1 receptors in the brain, stomach and pancreas to regulate appetite and glucose. Conceptual; in vivo efficacy is not yet established.

Partnering

Available for Early Out-Licensing

Available for out-licensing once proof of concept is in hand. The full package is shared under a CDA.

Request the Pipeline Package About Partnering

Every programme is in development and pre-approval. Product properties, including dosing interval and efficacy endpoints, are development targets and have not been established in vivo. Technical, market and development detail is available under an executed CDA.